Cellebrite DI (NASDAQ:CLBT) Sets New 52-Week High at $14.14

Cellebrite DI Ltd. (NASDAQ:CLBT)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $14.14 and last traded at $14.14, with a volume of 1546 shares. The stock had previously closed at $13.98.

Wall Street Analysts Forecast Growth

CLBT has been the topic of a number of recent research reports. Craig Hallum upped their target price on Cellebrite DI from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, April 1st. Needham & Company LLC increased their price objective on shares of Cellebrite DI from $13.50 to $14.00 and gave the stock a “buy” rating in a research note on Friday, May 24th. Bank of America boosted their target price on shares of Cellebrite DI from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, April 1st. Lake Street Capital initiated coverage on Cellebrite DI in a research report on Friday, April 19th. They set a “buy” rating and a $13.00 price target on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on Cellebrite DI from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, May 24th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $13.17.

Cellebrite DI Price Performance

The stock has a market capitalization of $2.89 billion, a PE ratio of -24.10, a P/E/G ratio of 1.90 and a beta of 1.50. The stock’s fifty day moving average is $11.87 and its 200-day moving average is $11.06.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, May 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. Cellebrite DI had a negative net margin of 32.57% and a positive return on equity of 417.94%. The business had revenue of $89.60 million for the quarter, compared to analyst estimates of $85.34 million. During the same period in the prior year, the company posted $0.03 EPS. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. On average, analysts forecast that Cellebrite DI Ltd. will post 0.34 EPS for the current year.

Institutional Trading of Cellebrite DI

Several institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC raised its stake in shares of Cellebrite DI by 75.0% during the 4th quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock worth $30,000 after buying an additional 1,500 shares during the period. Quarry LP purchased a new position in Cellebrite DI during the fourth quarter valued at $36,000. Central Asset Investments & Management Holdings HK Ltd acquired a new stake in shares of Cellebrite DI in the fourth quarter valued at about $113,000. Hennessy Advisors Inc. acquired a new stake in shares of Cellebrite DI in the fourth quarter valued at about $131,000. Finally, Russell Investments Group Ltd. increased its stake in shares of Cellebrite DI by 92.5% during the first quarter. Russell Investments Group Ltd. now owns 16,649 shares of the company’s stock worth $188,000 after purchasing an additional 8,001 shares in the last quarter. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.